These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 27353365)

  • 1. The ER structural protein Rtn4A stabilizes and enhances signaling through the receptor tyrosine kinase ErbB3.
    Hatakeyama J; Wald JH; Rafidi H; Cuevas A; Sweeney C; Carraway KL
    Sci Signal; 2016 Jun; 9(434):ra65. PubMed ID: 27353365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of Nrdp1 enhances ErbB2/ErbB3-dependent breast tumor cell growth.
    Yen L; Cao Z; Wu X; Ingalla ER; Baron C; Young LJ; Gregg JP; Cardiff RD; Borowsky AD; Sweeney C; Carraway KL
    Cancer Res; 2006 Dec; 66(23):11279-86. PubMed ID: 17145873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantity control of the ErbB3 receptor tyrosine kinase at the endoplasmic reticulum.
    Fry WH; Simion C; Sweeney C; Carraway KL
    Mol Cell Biol; 2011 Jul; 31(14):3009-18. PubMed ID: 21576364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuregulin-induced ErbB3 downregulation is mediated by a protein stability cascade involving the E3 ubiquitin ligase Nrdp1.
    Cao Z; Wu X; Yen L; Sweeney C; Carraway KL
    Mol Cell Biol; 2007 Mar; 27(6):2180-8. PubMed ID: 17210635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oligomerization of the Nrdp1 E3 ubiquitin ligase is necessary for efficient autoubiquitination but not ErbB3 ubiquitination.
    Printsev I; Yen L; Sweeney C; Carraway KL
    J Biol Chem; 2014 Mar; 289(12):8570-8. PubMed ID: 24519943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An RBCC protein implicated in maintenance of steady-state neuregulin receptor levels.
    Diamonti AJ; Guy PM; Ivanof C; Wong K; Sweeney C; Carraway KL
    Proc Natl Acad Sci U S A; 2002 Mar; 99(5):2866-71. PubMed ID: 11867753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-transcriptional mechanisms contribute to the suppression of the ErbB3 negative regulator protein Nrdp1 in mammary tumors.
    Ingalla EQ; Miller JK; Wald JH; Workman HC; Kaur RP; Yen L; Fry WH; Borowsky AD; Young LJ; Sweeney C; Carraway KL
    J Biol Chem; 2010 Sep; 285(37):28691-7. PubMed ID: 20628057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nrdp1-mediated ErbB3 degradation inhibits glioma cell migration and invasion by reducing cytoplasmic localization of p27(Kip1).
    Shi H; Gong H; Cao K; Zou S; Zhu B; Bao H; Wu Y; Gao Y; Tang Y; Yu R
    J Neurooncol; 2015 Sep; 124(3):357-64. PubMed ID: 26088461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nrdp1/FLRF is a ubiquitin ligase promoting ubiquitination and degradation of the epidermal growth factor receptor family member, ErbB3.
    Qiu XB; Goldberg AL
    Proc Natl Acad Sci U S A; 2002 Nov; 99(23):14843-8. PubMed ID: 12411582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KITENIN functions as a fine regulator of ErbB4 expression level in colorectal cancer via protection of ErbB4 from E3-ligase Nrdp1-mediated degradation.
    Sun EG; Lee KH; Ko YS; Choi HJ; Yang JI; Lee JH; Chung IJ; Paek YW; Kim H; Bae JA; Kim KK
    Mol Carcinog; 2017 Mar; 56(3):1068-1081. PubMed ID: 27648936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nrdp1 expression to predict clinical outcome and efficacy of adjuvant anthracyclines-based chemotherapy in breast cancer: A retrospective study.
    Jiao S; Liu W; Wu M; Peng C; Tang H; Xie X
    Cancer Biomark; 2015; 15(2):115-23. PubMed ID: 25519010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reticulon 4a promotes exocytosis in mammalian cells.
    Mukherjee RN; Levy DL
    Mol Biol Cell; 2019 Aug; 30(18):2349-2357. PubMed ID: 31318320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NOGO-A/RTN4A and NOGO-B/RTN4B are simultaneously expressed in epithelial, fibroblast and neuronal cells and maintain ER morphology.
    Rämö O; Kumar D; Gucciardo E; Joensuu M; Saarekas M; Vihinen H; Belevich I; Smolander OP; Qian K; Auvinen P; Jokitalo E
    Sci Rep; 2016 Oct; 6():35969. PubMed ID: 27786289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4-1 and NRDP1, in primary breast cancer.
    Luhtala S; Staff S; Kallioniemi A; Tanner M; Isola J
    BMC Cancer; 2018 Oct; 18(1):1045. PubMed ID: 30367623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reticulon and CLIMP-63 regulate nanodomain organization of peripheral ER tubules.
    Gao G; Zhu C; Liu E; Nabi IR
    PLoS Biol; 2019 Aug; 17(8):e3000355. PubMed ID: 31469817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-based mutagenesis of the substrate-recognition domain of Nrdp1/FLRF identifies the binding site for the receptor tyrosine kinase ErbB3.
    Bouyain S; Leahy DJ
    Protein Sci; 2007 Apr; 16(4):654-61. PubMed ID: 17384230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nrdp1S, short variant of Nrdp1, inhibits human glioma progression by increasing Nrdp1-mediated ErbB3 ubiquitination and degradation.
    Wu Y; Wang L; Bao H; Zou S; Fu C; Gong H; Gao Y; Tang Y; Yu R; Shi H
    J Cell Mol Med; 2016 Mar; 20(3):422-9. PubMed ID: 26612725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Membrane Protein Quantity Control at the Endoplasmic Reticulum.
    Printsev I; Curiel D; Carraway KL
    J Membr Biol; 2017 Aug; 250(4):379-392. PubMed ID: 27743014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of ErbB3 and its binding partners in breast cancer progression and resistance to hormone and tyrosine kinase directed therapies.
    Hamburger AW
    J Mammary Gland Biol Neoplasia; 2008 Jun; 13(2):225-33. PubMed ID: 18425425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nrdp1 inhibits growth of colorectal cancer cells by nuclear retention of p27.
    Lu H; Li H; Mao D; Zhu Z; Sun H
    Tumour Biol; 2014 Sep; 35(9):8639-43. PubMed ID: 24867101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.